Core Viewpoint - *ST Green Kang is divesting its photovoltaic film business by selling 100% equity of three subsidiaries to Jiangxi Raoxin New Energy Materials Co., Ltd. for cash, aiming to protect shareholder interests and improve financial health [1][4]. Group 1: Company Background - *ST Green Kang, originally focused on veterinary drug development and sales, shifted to the photovoltaic film industry in 2022 due to persistent losses in its core business [2]. - The company acquired Green Kang Yushan for 95 million yuan, despite its book value being only 160,350 yuan, indicating a significant overvaluation at the time of purchase [2][4]. Group 2: Financial Performance - The company has faced substantial losses, reporting a net loss of 222 million yuan in 2023, which is expected to increase to 445 million yuan in 2024, totaling over 700 million yuan in losses within two and a half years [4][5]. - As of June 2023, *ST Green Kang's debt-to-asset ratio surged to 105.82%, indicating a state of insolvency [5]. Group 3: Industry Context - The photovoltaic film industry experienced a downturn from 2023 to 2024, with oversupply leading to declining prices for POE, EVA, and EPE films, adversely affecting *ST Green Kang's profitability [5][6]. - The company's subsidiaries reported negative gross margins in 2024, with Green Kang Yushan at -19.28%, Green Kang Haining at -35.96%, and Green Kang New Energy at 0.41% [5]. Group 4: Strategic Implications - By divesting the loss-making photovoltaic film business, *ST Green Kang aims to refocus on its core veterinary products, enhancing its profitability and sustainability [7]. - The exit from the photovoltaic sector reflects a broader trend of companies withdrawing from the industry amid significant adjustments, with several other firms also choosing to leave [7][8].

Core Viewpoint - The animal health sector experienced a rise of 1.59% on September 26, with Bio-Pharmaceuticals leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.65% and 1.76% respectively [1] Group 1: Market Performance - The animal health sector's individual stock performance showed significant variations, with Bio-Pharmaceuticals closing at 9.34, up by 7.23%, and a trading volume of 1.0367 million shares, resulting in a turnover of 973 million yuan [1] - Other notable performers included Huisheng Biological at 20.68, up by 1.87%, and Ruipu Biological at 20.93, up by 1.60% [1] Group 2: Capital Flow - The animal health sector saw a net inflow of 86.5157 million yuan from institutional investors, while retail investors experienced a net outflow of 44.7995 million yuan [2] - The capital flow data indicates that major stocks like Bio-Pharmaceuticals had a net inflow of 12.63% from institutional investors, despite a significant outflow from retail and speculative investors [3]

Market Overview - On September 25, the animal health sector declined by 1.62% compared to the previous trading day, with the leading stock, Driveline, experiencing a drop of 4.04% [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the animal health sector showed notable declines: - Driveline (Code: 838275) closed at 9.50, down 4.04% with a trading volume of 19,300 lots [1] - Shunlian Bio (Code: 688098) closed at 10.43, down 3.43% with a trading volume of 76,300 lots [1] - Yongshun Bio (Code: 839729) closed at 9.74, down 2.89% with a trading volume of 20,800 lots [1] - Other notable declines include *ST Green Health (Code: 002868) down 2.39% and Shoufeng Holdings (Code: 002141) down 2.33% [1] Capital Flow - The animal health sector saw a net outflow of 113 million yuan from institutional investors, while retail investors experienced a net inflow of 61.16 million yuan [1] - The following stocks had significant capital flow: - Zhongmu Co. (Code: 600195) had a net inflow of 986,800 yuan from institutional investors [2] - Pulaike (Code: 603566) saw a net inflow of 764,200 yuan from retail investors [2] - *ST Green Health (Code: 002868) experienced a net outflow of 6.71 million yuan from institutional investors [2]

Core Viewpoint - *ST绿康 plans to sell three wholly-owned subsidiaries for 0 yuan, raising regulatory concerns due to the significant loss in asset value since their acquisition [1][4]. Group 1: Company Overview - *ST绿康 is a high-tech enterprise focused on the research, production, and sales of veterinary drugs, plant protection products, food additives, and photovoltaic film [1]. - The company was listed on the Shenzhen Stock Exchange in May 2017 and has been experiencing continuous losses since then [1][3]. Group 2: Asset Sale Details - The subsidiaries being sold include绿康(玉山)胶膜材料有限公司, 绿康(海宁)胶膜材料有限公司, and 绿康新能(上海)进出口贸易有限公司 [1]. - The sale price of 0 yuan is in stark contrast to the 95 million yuan paid for 绿康玉山 in January 2023, which was based on a valuation of 9570 million yuan using the income approach [2][4]. - The combined book value of the three subsidiaries has reached -1 billion yuan by the end of 2024, with 绿康玉山 alone incurring losses of 2.03 billion yuan in 2024 [3][4]. Group 3: Financial Performance - From 2022 to 2024, *ST绿康's revenue showed fluctuations: 3.30 billion yuan, 5.07 billion yuan, and 6.49 billion yuan, with net profits of -1.22 billion yuan, -2.22 billion yuan, and -4.45 billion yuan respectively [3]. - The company has faced a cumulative loss of nearly 700 million yuan over two years since entering the photovoltaic sector [3]. Group 4: Regulatory and Market Response - The transaction has drawn scrutiny from the Shenzhen Stock Exchange, which is concerned about the fairness and rationale behind the asset valuation and potential harm to shareholders [1][4]. - As of September 25, *ST绿康's stock price was 27.33 yuan per share, reflecting a decline of 2.39% and a total market capitalization of 4.248 billion yuan [5].

交易标的的评估情况。图/企业公告截图 *ST绿康表示，近年来，随着光伏终端装机需求快速提升，巨量资本涌入光伏行业，产能扩张加速推进。在此背景下，光伏行业整体出现供需错配，产业链 竞争加剧，各环节产品销售价格迅速回落，企业盈利能力下滑，大部分企业出现经营亏损。 据其介绍，2023年和2024年，绿康玉山的净利润分别为-5591.78万元和-20325.36万元，绿康海宁的净利润分别为-2148.88万元和-15073.18万元，经营业绩不 及预期，持续出现较大亏损。绿康玉山和绿康海宁作为上市公司光伏胶膜业务的主要运营主体，其业绩表现不佳使上市公司整体盈利能力承压。 据悉，这是因为标的公司亏损严重，影响了上市公司的整体业绩。 | 交易标的公司名称 | 基准日 | 评估方法 | 评估结果(万 | 增值率/溢价 | 本次拟交易的 | | --- | --- | --- | --- | --- | --- | | | | | 元) | 率 (%) | 权益比例 | | 绿康玉山 | 2024 年 12月 3 | 资产基础法 | -64.86 | 98.12 | 100% | | | 1日 | | | | | | 绿康海 ...

Core Viewpoint - *ST Green Kang (002868.SZ) plans to sell three wholly-owned subsidiaries to Jiangxi Raoxin New Energy Materials Co., Ltd. for a price of 0 yuan, raising regulatory concerns due to the significant loss in asset value from a previous acquisition of 95 million yuan [1][3][4]. Group 1: Transaction Details - The transaction involves the sale of 100% equity in Green Kang (Yushan), Green Kang (Haining), and Green Kang New Energy, all for a total price of 0 yuan [3][8]. - The assessment of the subsidiaries shows a negative valuation for Green Kang (Yushan) and Green Kang (Haining), with values of -648.6 thousand yuan and -28.7762 million yuan respectively, while Green Kang New Energy has a positive valuation of 8.5807 million yuan [2][4]. Group 2: Financial Performance - Green Kang (Yushan) reported losses of 14.9363 million yuan in 2022, 55.9178 million yuan in 2023, and an expected loss of 203.2536 million yuan in 2024 [5]. - The combined book value of the three subsidiaries reached -100.0508 million yuan by the end of the previous year, indicating severe financial distress [5]. Group 3: Market Context - The solar industry experienced rapid growth followed by a significant downturn, leading to overcapacity and financial challenges for *ST Green Kang [5][6]. - Despite initial optimism regarding the acquisition of Green Kang (Yushan) due to its partnership with JinkoSolar, market conditions quickly deteriorated, resulting in substantial losses [4][5]. Group 4: Operational Status - Green Kang (Haining) was established in January 2023 with ambitious plans to produce 800 million square meters of solar film but has since halted operations [6][8]. - Green Kang New Energy, founded in November 2023, also ceased operations, indicating a complete shutdown of the newly established subsidiaries [8].

Core Viewpoint - The animal health sector experienced a decline of 1.49% on September 24, with *ST Lvkang leading the drop, while the overall market indices showed positive performance with the Shanghai Composite Index up by 0.83% and the Shenzhen Component Index up by 1.8% [1][2]. Group 1: Market Performance - The animal health sector's decline was primarily driven by *ST Lvkang, which closed at 28.00, down by 1.16% [2]. - The sector's individual stock performance varied, with notable gainers including Yongshun Biological (+3.72%) and Shilian Biological (+1.69%) [1][2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector showed significant activity, with Yongshun Biological recording a volume of 24,700 hands and a transaction value of 24.36 million [1]. - The sector saw a net outflow of 75.79 million from institutional investors, while retail investors contributed a net inflow of 42.98 million [2][3]. Group 3: Individual Stock Capital Flow - *ST Lvkang experienced a significant net outflow of 10.63 million from institutional investors, indicating a negative sentiment towards the stock [3]. - Conversely, Shilian Biological had a net inflow of 10.41 million from institutional investors, reflecting stronger institutional interest [3].

Core Viewpoint - *ST绿康 plans to sell three wholly-owned subsidiaries at a price of 0 yuan, raising concerns about the company's decision-making and future direction in the market [1][2]. Group 1: Company Actions - The company intends to sell 100% equity of three subsidiaries, including Green Kang (Yushan) Film Materials Co., Ltd., Green Kang (Haining) Film Materials Co., Ltd., and Green Kang New Energy (Shanghai) Import and Export Trade Co., Ltd. [1] - In January 2023, the company invested 950 million yuan to acquire Green Kang (Yushan), aiming to enter the photovoltaic film industry, which was experiencing rapid growth at that time [1][2]. - The subsidiaries have incurred significant losses, with Green Kang (Yushan) reporting a loss of 55.9 million yuan in 2023 and projected losses of 203.25 million yuan in 2024 [1][2]. Group 2: Market Reactions - The decision to sell the subsidiaries at 0 yuan has led to widespread market skepticism regarding the rationale and fairness of the valuation [2]. - The Shenzhen Stock Exchange has raised questions about the reasonableness of the transaction, and investors are concerned about the company's decision-making capabilities [2]. Group 3: Recommendations for Company - The company needs to provide detailed disclosures about the transaction, including the basis for the valuation and the reasons for the drastic drop in value from 950 million yuan to 0 yuan [3]. - It is essential for the company to ensure transparency in the transaction process and strengthen internal controls to align decisions with shareholder interests [3]. - Regular communication with investors through meetings and calls is necessary to address concerns and rebuild trust in the management [3].

Core Viewpoint - *ST Green Kang plans to sell three wholly-owned subsidiaries to Jiangxi Raoxin New Energy Materials Co., Ltd. for a price of 0 yuan, raising regulatory concerns due to the significant loss incurred from the previous acquisition of one of these subsidiaries, Green Kang Yushan [1][3][4]. Group 1: Transaction Details - The transaction involves the sale of 100% equity of Green Kang Yushan, Green Kang Haining, and Green Kang New Energy, with a total cash consideration of 0 yuan [3][8]. - Green Kang Yushan was acquired for 95 million yuan in January 2023, but is now being sold for 0 yuan, prompting questions about the fairness and reasonableness of the valuation [4][6]. - The combined book value of the three subsidiaries has reached -100.05 million yuan as of the end of last year [4][6]. Group 2: Financial Performance - Green Kang Yushan reported losses of 14.94 million yuan in 2022, 55.92 million yuan in 2023, and an estimated 203.25 million yuan in 2024 [4][6]. - Green Kang Haining and Green Kang New Energy have also ceased operations, contributing to the uncertainty of ongoing profitability [6][8]. Group 3: Industry Context - The photovoltaic industry has experienced rapid growth followed by a significant downturn, impacting the financial viability of companies like *ST Green Kang [5][6]. - The initial acquisition of Green Kang Yushan was based on its established partnership with JinkoSolar, a key player in the photovoltaic sector, but market conditions have since deteriorated [4][5].

Core Viewpoint - Green Kang Biochemical Co., Ltd. plans to sell 100% equity of three subsidiaries to Jiangxi Raoxin New Energy Materials Co., Ltd. for a transaction price of 0 yuan, which constitutes a related party transaction [1][2]. Group 1: Transaction Details - The transaction involves the sale of Green Kang (Yushan) Film Material Co., Ltd., Green Kang (Haining) Film Material Co., Ltd., and Green Kang New Energy (Shanghai) Import and Export Trade Co., Ltd. [1] - As of December 31, 2024, the combined book value of the three subsidiaries is -100.05 million yuan, with an assessed value of -20.84 million yuan, resulting in a value increase rate of 79.17% [1][2]. - The assessment methods used include the asset-based approach and income approach for Green Kang Yushan, while only the asset-based approach was used for Green Kang Haining and Green Kang New Energy [1][4]. Group 2: Financial Performance - Green Kang Yushan's revenue for 2024 is projected at 28.52 million yuan, a year-on-year increase of 82.77%, but it is expected to incur a net loss of 20.33 million yuan [2]. - Green Kang Haining is expected to generate revenue of 8.89 million yuan with a net loss of 15.07 million yuan, while Green Kang New Energy is projected to have revenue of 11.64 million yuan and a net loss of 0.35 million yuan [2]. - The assessment agency noted that the subsidiaries are facing intense competition in the photovoltaic film industry, leading to declining product prices and significant uncertainty regarding their future profitability [2]. Group 3: Valuation Adjustments - Revenue forecasts for Green Kang Yushan were adjusted downward due to ongoing challenges, with expected revenue from 2025 to 2029 revised from 17.43 million yuan to 81.99 million yuan [3]. - Following the adjustments, the assessed value for Green Kang Yushan decreased from -12 million yuan to -40 million yuan, and the overall assessed value for the three subsidiaries changed from -18.74 million yuan to -20.84 million yuan [3]. - Despite the valuation adjustments, the transaction price remains at 0 yuan as agreed upon by both parties [3]. Group 4: Compliance with Valuation Methods - The use of only the asset-based approach for Green Kang Haining and Green Kang New Energy was justified due to their loss-making and suspended operational status, making future income predictions challenging [4]. - The assessment agency confirmed that the approach complies with relevant regulations and industry practices, as there are precedents for using a single valuation method in similar transactions [4].